Non Human Primate Core

核心B摘要 非人灵长类(NHP)核心寻求巩固对NHP实验的监督和绩效 “人巨细胞病毒/SIV疫苗诱导的免疫学和病毒学基础”项目方案 将“复制阻止功效”转化为一个由经验丰富的研究人员组成的结构化核心。《环球报》 核心的目标是提供领导和技术专长，以确保一致性和质量控制 在动物选择、研究方案的执行、实验程序的应用、动物观察 和必要的数据收集，以满足项目和其他核心牵头调查人员的目标。要完成 为此，中心将管理和直接监督项目的所有NHP研究，包括：1)动物选择； 2)动物饲养和一般饲养；3)实验程序和临床管理；4)标本 收集和处理；5)尸检研究；以及6)动物人口统计的获取和管理， 生理、临床和病理资料。计划项目的总体目标是确定 在RhCMV/SIV中负责完全阻止和随后清除新生SIV感染的机制- 免疫恒河猴，包括对MHC-E限制性表位识别的有效性要求， 细胞如何介导复制抑制和IL-15信号作为预见性转录因子的作用 签名。NHP核心将提供所需的专业知识和技术支持，以确保成功 完成支持项目1的多方面和广泛的NHP研究方案--免疫学和 RhCMV/SIV疫苗介导的SIV复制抑制效应的病毒学特征，项目2- 疫苗接种后原发SIV感染的体内T细胞(和整体免疫)拦截的特征 与差异反应编程的RhCMV/SIV载体(MHC-E与MHC-II与MHC-Ia)和 常规SIV疫苗和项目3--最小MHC-E限制性SIV表位靶向的确定 RhCMV/SIV疫苗介导的SIV复制抑制效应所必需的。

CORE B SUMMARY The Nonhuman Primate (NHP) Core seeks to consolidate supervision and performance of the NHP experimental protocols of the Program Project entitled “Immunologic and virologic basis of RhCMV/SIV vaccine-induced replication arrest efficacy” into a structured Core composed of highly experienced research personnel. The global objective of the Core is to provide leadership and technical expertise to ensure consistency and quality control in animal selection, execution of study protocols, application of experimental procedures, animal observations and data collection necessary to meet the objectives of Project and other Core lead investigators. To accomplish this, the Core will manage and directly supervise all NHP studies for the Project including: 1) animal selection; 2) animal housing and general husbandry; 3) experimental procedures and clinical management; 4) specimen collection and processing; 5) necropsy studies; and 6) acquisition and management of animal demographic, physiologic, clinical, and pathologic data. The overall objective of the Program Project is to determine the mechanisms responsible for complete arrest and subsequent clearance of nascent SIV infection in RhCMV/SIV- immunized rhesus macaques, including the requirement for MHC-E restricted epitope recognition for efficacy, how cells mediate replication arrest and the role of IL-15 signaling identified as a predictive transcriptomic signature. The NHP Core will provide the expertise and technical support required to insure successful completion of the multifaceted and extensive NHP research protocols supporting Project 1 – Immunologic and virologic characterization of RhCMV/SIV vaccine-mediated SIV “replication arrest” efficacy, Project 2 – Characterization of the in vivo T cell (and overall immune) interception of primary SIV infection after vaccination with differentially response programmed RhCMV/SIV vectors (MHC-E vs. MHC-II vs. MHC-Ia) and a conventional SIV vaccine, and Project 3 – Determination of the minimal MHC-E-restricted SIV epitope targeting required for RhCMV/SIV vaccine-mediated SIV “replication arrest” efficacy.